Mark Cascione

1.3k total citations
17 papers, 169 citations indexed

About

Mark Cascione is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Mark Cascione has authored 17 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 6 papers in Neurology and 4 papers in Molecular Biology. Recurrent topics in Mark Cascione's work include Multiple Sclerosis Research Studies (15 papers), Peripheral Neuropathies and Disorders (4 papers) and Sphingolipid Metabolism and Signaling (4 papers). Mark Cascione is often cited by papers focused on Multiple Sclerosis Research Studies (15 papers), Peripheral Neuropathies and Disorders (4 papers) and Sphingolipid Metabolism and Signaling (4 papers). Mark Cascione collaborates with scholars based in United States, Switzerland and Canada. Mark Cascione's co-authors include Lesley Schofield, Fernando Dangond, Xiangyi Meng, Bruce Cree, Nadia Tenenbaum, David Brassat, Jason P. Mendoza, Aaron Miller, Erin E. Longbrake and Edward Fox and has published in prestigious journals such as Neurology, Journal of Neurology Neurosurgery & Psychiatry and Multiple Sclerosis Journal.

In The Last Decade

Mark Cascione

17 papers receiving 164 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Cascione United States 9 129 49 44 37 33 17 169
Elżbieta Jasińska Poland 6 106 0.8× 36 0.7× 24 0.5× 49 1.3× 30 0.9× 12 176
Veronika Tichá Czechia 5 104 0.8× 24 0.5× 54 1.2× 26 0.7× 38 1.2× 10 144
Marcos Papais Alvarenga Brazil 9 163 1.3× 71 1.4× 21 0.5× 52 1.4× 49 1.5× 14 198
Brian Steingo United States 7 122 0.9× 62 1.3× 9 0.2× 39 1.1× 36 1.1× 12 161
Ratnakar Pingili United States 6 156 1.2× 74 1.5× 20 0.5× 38 1.0× 24 0.7× 15 189
Mathias Due Buron Denmark 8 203 1.6× 60 1.2× 14 0.3× 54 1.5× 55 1.7× 13 218
Enrique Gómez‐Figueroa Mexico 9 75 0.6× 97 2.0× 18 0.4× 16 0.4× 21 0.6× 28 180
Nisha Lucas United States 5 269 2.1× 76 1.6× 36 0.8× 194 5.2× 25 0.8× 9 313
I. Kupfer France 6 37 0.3× 16 0.3× 38 0.9× 14 0.4× 21 0.6× 11 153
Silva Soldo-Butković Croatia 6 45 0.3× 21 0.4× 12 0.3× 21 0.6× 22 0.7× 14 117

Countries citing papers authored by Mark Cascione

Since Specialization
Citations

This map shows the geographic impact of Mark Cascione's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Cascione with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Cascione more than expected).

Fields of papers citing papers by Mark Cascione

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Cascione. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Cascione. The network helps show where Mark Cascione may publish in the future.

Co-authorship network of co-authors of Mark Cascione

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Cascione. A scholar is included among the top collaborators of Mark Cascione based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Cascione. Mark Cascione is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bar‐Or, Amit, et al.. (2025). Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management. Neurology Neuroimmunology & Neuroinflammation. 12(4). e200427–e200427. 7 indexed citations
2.
Vermersch, Patrick, Jiwon Oh, Mark Cascione, et al.. (2020). Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders. 43. 102158–102158. 8 indexed citations
3.
Hunter, Samuel F., Florian P. Thomas, Mark Cascione, et al.. (2020). Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰. Multiple Sclerosis and Related Disorders. 45. 102346–102346. 1 indexed citations
4.
Longbrake, Erin E., Yang Mao‐Draayer, Mark Cascione, et al.. (2020). Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal. 27(6). 883–894. 35 indexed citations
5.
6.
Cascione, Mark, Nadia Tenenbaum, Jeanette Wendt, et al.. (2018). Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. Multiple Sclerosis and Related Disorders. 25. 50–56. 10 indexed citations
7.
8.
Cree, Bruce, Douglas L. Arnold, Mark Cascione, et al.. (2018). Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Therapeutic Advances in Neurological Disorders. 11. 1276995906–1276995906. 20 indexed citations
9.
Cascione, Mark, Jeanette Wendt, Bruce Cree, et al.. (2017). PREFERMS study: post hoc analyses of patient retention, key clinical outcomes and patient satisfaction in an African-American patient subgroup (P6.382). Neurology. 88(16_supplement). 1 indexed citations
10.
Naismith, Robert T., Mark Cascione, Luigi Maria Edoardo Grimaldi, et al.. (2017). Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study (S31.004). Neurology. 88(16_supplement). 2 indexed citations
11.
Naismith, Robert T., Mark Cascione, Luigi Maria Edoardo Grimaldi, et al.. (2017). Preliminary results of the opera i and opera ii open-label extension study. Journal of Neurology Neurosurgery & Psychiatry. 88(5). e1.90–e1. 3 indexed citations
12.
13.
Cascione, Mark, Mark S. Freedman, Mark Agius, et al.. (2014). First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 3(5). 620–628. 13 indexed citations
14.
15.
16.
Singer, B., Sibyl Wray, Tamara Miller, et al.. (2012). Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 1(2). 87–94. 14 indexed citations
17.
Wray, Sibyl, Robert W. Armstrong, Craig Herrman, et al.. (2011). Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opinion on Drug Delivery. 8(12). 1543–1553. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elżbieta Jasińska Breakdown of academic impact, for papers by Veronika Tichá Breakdown of academic impact, for papers by Marcos Papais Alvarenga Breakdown of academic impact, for papers by Brian Steingo Breakdown of academic impact, for papers by Ratnakar Pingili Breakdown of academic impact, for papers by Mathias Due Buron Breakdown of academic impact, for papers by Enrique Gómez‐Figueroa Breakdown of academic impact, for papers by Nisha Lucas Breakdown of academic impact, for papers by I. Kupfer Breakdown of academic impact, for papers by Silva Soldo-Butković
Rankless by CCL
2026